Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Neurocognitive Changes After CAR T-Cell Therapy for NHL Similar to Other Cancers
April 20th 2022With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.
Read More
Higher Risk of CV Mortality Seen in Patients With MM Compared With General Population
April 14th 2022While studies have explored risks among patients with multiple myeloma, recent research is the first to compare cardiovascular mortality risk in multiple myeloma to that of the general population.
Read More
LMOD3 Gene Variant Identified in Hypersomnolence Case With Potential Kleine-Levin Syndrome
April 10th 2022Kleine-Levin syndrome is rare and difficult to diagnose, especially when symptoms are atypical. Recent research points to LMOD3 variations as a potential diagnostic marker if confirmed by further research.
Read More
Examining Changes in STEMI Treatment Strategies and Outcomes in CKD Over Time
April 9th 2022Despite underrepresentation in clinical trials of acute coronary syndrome treatments, a recent study suggests treatment strategies and outcomes in chronic kidney disease patients with ST-elevation myocardial infarctions (STEMI) have improved over time.
Read More
Study Finds LCOR May Be a Viable Target to Increase Efficacy of Immunotherapy in TNBC
April 8th 2022Therapy resistance remains a challenge with immune checkpoint inhibitors, and a new study proposes targeting ligand-dependent corepressor (LCOR) in addition to known immune targets to improve outcomes.
Read More
Real-World Data Suggest Fidaxomicin Reduces Clostridioides difficile Reinfection Versus Vancomycin
April 1st 2022Both fidaxomicin and vancomycin are recommended for treatment of Clostridioides difficile infections, but real-world data suggest fidaxomicin should be the go-to treatment option.
Read More
Case Report and Review Highlight Importance of Identifying Osteolytic Lesions in MPNs
April 1st 2022A recent report details the first reported case of an osteolytic lesion in polycythemia vera and reviews current literature on osteolytic lesions in myeloproliferative neoplasms (MPNs) overall.
Read More
Study Finds Low Natural Antibody Response to Clostridioides difficile
March 27th 2022The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a new exploratory study.
Read More
Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL
March 19th 2022Mantle cell lymphoma is a difficult cancer type with high relapse rates, but novel targeted approaches such as CAR T-cell therapy hold promise for more successful response rates in the future.
Read More
Study Finds C difficile Infection Manageable in Primary Care Settings With Specialist Guidance
March 17th 2022Cases of Clostridioides difficile (C diff) have increasingly been reported outside of typical settings, and a survey of general practitioners in France found that many cases can be managed without hospitalization.
Read More
Potential Link Found Between Thrombotic Events, Mortality in Patients With PV, ET
March 13th 2022Patients with polycythemia vera (PV) or essential thrombocythemia (ET) had a higher risk of thrombotic events than the general population, which was associated with mortality in a recent study.
Read More
Elevated Repolarization Dispersion Linked With LV Diastolic Discoordination in Pediatric PAH
March 12th 2022Repolarization dispersion has been linked to echocardiographic measures of diastolic dysfunction in past research, and a recent study found it potentially indicative of pulmonary arterial hypertension severity.
Read More
CAR T-Cell Therapy in Hematological Cancers: Current Challenges and Future Potential
March 6th 2022Although chimeric antigen receptor (CAR) T-cell treatments have shown efficacy in certain cancers, targeting multiple antigens and overcoming production limitations may advance the field and make this therapy more effective and accessible.
Read More